表紙
市場調查報告書

全球前列腺癌診斷及治療市場:各種類、診斷法、治療方法、地區 - 成長,趨勢,預測(2018年∼2023年)

Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 660546
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球前列腺癌診斷及治療市場:各種類、診斷法、治療方法、地區 - 成長,趨勢,預測(2018年∼2023年) Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年04月01日內容資訊: 英文 112 Pages
簡介

全球前列腺癌診斷及治療市場,預計從2018年到2023年以6.1%的年複合成長率發展。在2016年中,以收益為準佔了最大的佔有率的北美地區帶動市場。

本報告提供全球前列腺癌診斷及治療市場調查,市場概要,各類型、診斷法、治療方法、地區的市場規模的變化與預測,市場趨勢,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題

  • 市場成長要素
    • 前列腺癌的罹患率高
    • 治療藥的創新與基因學及蛋白質體學領域的發展
    • 醫藥品開發領域的公共部門及民間部門的資金籌措的增加
    • 癌症、腫瘤診斷及治療藥的技術發展
  • 市場阻礙因素
    • 診斷檢驗相關的成本高
    • 臨床試驗的成功率低
    • 治療的副作用
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各類型
    • 良性前列腺肥大症
    • 前列腺腺癌
    • 小細胞癌症
    • 其他
  • 各診斷法
    • 細胞切片檢查
    • 數位直腸檢驗
    • 臨床檢驗
    • 診斷成像
  • 各治療法
    • 化療
    • 近接治療
    • 放射線治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要業者

  • Abbott
  • AstraZeneca
  • Astellas Pharma Inc.
  • Bayer AG
  • BioMark Diagnostics Inc.
  • Sanofi
  • Ipsen
  • TOLMAR Pharmaceuticals, Inc.
  • Indevus Pharmaceuticals Inc.
  • Dendreon Inc.
  • 其他企業

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 47468

Market Overview

The prostate cancer diagnostics and therapy market is expected to register a CAGR of nearly 6.1% during the forecast period, 2019-2024.

  • The major factor driving the growth of the market studied is aging population and high prevalence rate of prostate cancer. Prostate cancer is the second most common type of cancer in male population. About 80% of men who reach 80 years of age are diagnosed with it.
  • As per the estimates provided by the American Cancer Society, in 2018, the United States is expected to witness over 164,690 new cases of prostate cancer, with over 29,430 related deaths. Nearly 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime.
  • In addition, according to the United States Census Bureau's Statistics, the total number of people aged 65 and older exceeds 50 million as of 2017, and the number of elderly is projected to increase by almost 18 million during 2020-2030. The number of people aged 85 and older is expected to triple from an estimated 6 million of today to nearly 20 million, by 2060. The risk of developing prostate cancer increases significantly with age, and rise in geriatric population is one of the leading factors that contribute to the expansion of the market.

Scope of the Report

The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer.

Key Market Trends

The Prostate-specific Antigen (PSA) Testing Segment is Expected to Grow at Rapid Pace.

Prostate-specific Antigen (PSA) is a protein produced by prostate cells. Therefore, the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post treatment to check if the cancer relapses. PSA testing is an important tool for detecting prostate cancer, which measures the level of PSA in a man's blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. The PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people being affected by prostate cancer. It has more market value in the countries with high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer.

PSA testing is anticipated to reduce the likelihood of death from prostate cancer. Refinements of the prostate-specific antigen (PSA) test have been developed to reduce the number of false positive results. Therefore, due to the rising prevalence of prostate cancer, the market is expected to witness high growth rate, over the forecast period.

United States is Expected to Retain the Largest Market Share During the Period of Forecast.

Prostate cancer is considered as one of the most common cancers among American men, and more than 60% of all prostate cancers are diagnosed in men older than 65. According to the American Cancer Society's, 2019, there are about 174,650 new cases of prostate cancer accounting for 31,620 deaths. Hence, it is considered to have an early diagnosis of the condition. In case of the treatment, the early stages of prostate cancer are treated by radiation therapy and for the late stages, where it has spread beyond the prostate gland, hormone therapy, chemotherapy, and or immunotherapy treatments, are recommended. In the case of benign prostatic hyperplasia (BPH), resectoscopy is the major treatment procedure. Zytiga and Xtandi are the major therapeutics that are used for treatment. Zytiga is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). With promising pipeline drugs, such as Apalutamide, the market of therapeutics is expected to increase.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc, Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
      • 5.2.1.1 Tissue Biopsy
      • 5.2.1.2 Transrectal Ultrasound
      • 5.2.1.3 Clinical Laboratory Examination
      • 5.2.1.3.1 Prostate-specific Antigen Testing
      • 5.2.1.3.2 Urine Testing
      • 5.2.1.4 Diagnostic Imaging
    • 5.2.2 Treatment
      • 5.2.2.1 Surgery
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Therapeutics
      • 5.2.2.3.1 Hormone Therapy
      • 5.2.2.3.2 Chemotherapy
      • 5.2.2.3.3 Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Ipsen SA
    • 6.1.2 Bayer AG
    • 6.1.3 Astellas Pharma Inc.
    • 6.1.4 Abbvie Inc.
    • 6.1.5 Dendreon Pharmaceuticals LLC
    • 6.1.6 AstraZeneca PLC
    • 6.1.7 Sanofi-Aventis
    • 6.1.8 Tolmar Inc.
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Hologic Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top